414 related articles for article (PubMed ID: 21768453)
1. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
Coombes RC; Bliss JM; Espie M; Erdkamp F; Wals J; Tres A; Marty M; Coleman RE; Tubiana-Mathieu N; den Boer MO; Wardley A; Kilburn LS; Cooper D; Thomas MW; Reise JA; Wilkinson K; Hupperets P
J Clin Oncol; 2011 Aug; 29(24):3247-54. PubMed ID: 21768453
[TBL] [Abstract][Full Text] [Related]
2. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Roché H; Fumoleau P; Spielmann M; Canon JL; Delozier T; Serin D; Symann M; Kerbrat P; Soulié P; Eichler F; Viens P; Monnier A; Vindevoghel A; Campone M; Goudier MJ; Bonneterre J; Ferrero JM; Martin AL; Genève J; Asselain B
J Clin Oncol; 2006 Dec; 24(36):5664-71. PubMed ID: 17116941
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
[TBL] [Abstract][Full Text] [Related]
5. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
[TBL] [Abstract][Full Text] [Related]
6. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
Polyzos A; Malamos N; Boukovinas I; Adamou A; Ziras N; Kalbakis K; Kakolyris S; Syrigos K; Papakotoulas P; Kouroussis C; Karvounis N; Vamvakas L; Christophyllakis C; Athanasiadis A; Varthalitis I; Georgoulias V; Mavroudis D
Breast Cancer Res Treat; 2010 Jan; 119(1):95-104. PubMed ID: 19636702
[TBL] [Abstract][Full Text] [Related]
7. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
[TBL] [Abstract][Full Text] [Related]
8. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
[TBL] [Abstract][Full Text] [Related]
9. Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study.
Bulent Akinci M; Algin E; Inal A; Odabas H; Berk V; Coskun U; Uyeturk U; Isikdogan A; Aksoy S; Civelek B; Sevinc A; Buyukberber S
J BUON; 2013; 18(2):314-20. PubMed ID: 23818340
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.
Spielmann M; Roché H; Delozier T; Canon JL; Romieu G; Bourgeois H; Extra JM; Serin D; Kerbrat P; Machiels JP; Lortholary A; Orfeuvre H; Campone M; Hardy-Bessard AC; Coudert B; Maerevoet M; Piot G; Kramar A; Martin AL; Penault-Llorca F
J Clin Oncol; 2009 Dec; 27(36):6129-34. PubMed ID: 19917839
[TBL] [Abstract][Full Text] [Related]
11. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.
Eiermann W; Pienkowski T; Crown J; Sadeghi S; Martin M; Chan A; Saleh M; Sehdev S; Provencher L; Semiglazov V; Press M; Sauter G; Lindsay MA; Riva A; Buyse M; Drevot P; Taupin H; Mackey JR
J Clin Oncol; 2011 Oct; 29(29):3877-84. PubMed ID: 21911726
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.
Ramaswamy B; Povoski SP; Rhoades C; Allen J; Hauger M; Young D; Burak W; Farrar W; Yee L; Kendra K; Somasundaram S; Orlowski RZ; Shapiro CL
Breast Cancer Res Treat; 2005 Sep; 93(1):67-74. PubMed ID: 16184461
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
von Minckwitz G; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; Untch M
J Clin Oncol; 2010 Apr; 28(12):2015-23. PubMed ID: 20308671
[TBL] [Abstract][Full Text] [Related]
14. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Mavroudis D; Matikas A; Malamos N; Papakotoulas P; Kakolyris S; Boukovinas I; Athanasiadis A; Kentepozidis N; Ziras N; Katsaounis P; Saloustros E; Georgoulias V;
Ann Oncol; 2016 Oct; 27(10):1873-8. PubMed ID: 27502729
[TBL] [Abstract][Full Text] [Related]
15. Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).
Saloustros E; Malamos N; Boukovinas I; Kakolyris S; Kouroussis C; Athanasiadis A; Ziras N; Kentepozidis N; Makrantonakis P; Polyzos A; Christophyllakis C; Georgoulias V; Mavroudis D
Breast Cancer Res Treat; 2014 Dec; 148(3):591-7. PubMed ID: 25399229
[TBL] [Abstract][Full Text] [Related]
16. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
; Basser RL; O'Neill A; Martinelli G; Green MD; Peccatori F; Cinieri S; Coates AS; Gelber RD; Aebi S; Castiglione-Gertsch M; Viale G; Price KN; Goldhirsch A
J Clin Oncol; 2006 Jan; 24(3):370-8. PubMed ID: 16421418
[TBL] [Abstract][Full Text] [Related]
17. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
Gogas H; Dafni U; Karina M; Papadimitriou C; Batistatou A; Bobos M; Kalofonos HP; Eleftheraki AG; Timotheadou E; Bafaloukos D; Christodoulou C; Markopoulos C; Briasoulis E; Papakostas P; Samantas E; Kosmidis P; Stathopoulos GP; Karanikiotis C; Pectasides D; Dimopoulos MA; Fountzilas G
Breast Cancer Res Treat; 2012 Apr; 132(2):609-19. PubMed ID: 22187126
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial.
Ejlertsen B; Tuxen MK; Jakobsen EH; Jensen MB; Knoop AS; Højris I; Ewertz M; Balslev E; Danø H; Vestlev PM; Kenholm J; Nielsen DL; Bechmann T; Andersson M; Cold S; Nielsen HM; Maae E; Carlsen D; Mouridsen HT
J Clin Oncol; 2017 Aug; 35(23):2639-2646. PubMed ID: 28661759
[TBL] [Abstract][Full Text] [Related]
19. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
